FDA Releases Draft Guidance on Biosimilarity
Draft guidance addresses the use of clinical pharmacology studies to determine biosimilarity of biologics.
FDA has released draft guidance on the use of clinical pharmacology studies to determine if a proposed therapeutic biologic product is biosimilar to its reference product. The guidance pertains to products that require pharmacokinetic and pharmacodynamics data to demonstrate biosimilarity. The guidance addresses clinical pharmacology testing for biosimilar products, developing an appropriate clinical pharmacology database, and designing clinical trials.
The draft guidance is one in a series by FDA for the implementation of the Biologics Price Competition Act of 2009. FDA intends the guidance to “assist sponsors in designing clinical pharmacology studies that can support an application submitted under section 351(k) of the Public Health Service Act (PHS Act).” According to FDA, the guidance may also be helpful for the development of certain products under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.
Source: FDA.gov
Guidance on Quality Culture Standards
June 3rd 2025Matt Cushing, VP of Quality and Science, Nelson Labs, and Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs Company, discuss PDA/ANSI Standard 06-2025: Assessment of Quality Culture Guidance Documents, Models, and Tools, which was published in February 2025.
